Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review.

Autor: Lewis RA; Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, California, USA., Cornblath DR; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Hartung HP; Department of Neurology, UKD and Center for Neurology and Neuropsychiatry, LVR Klinikum, Heinrich Heine University, Düsseldorf, Germany., Sobue G; Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Lawo JP; CSL Behring, Marburg, King of Prussia, Pennsylvania, USA., Mielke O; CSL Behring, Marburg, King of Prussia, Pennsylvania, USA., Durn BL; CSL Behring, Marburg, King of Prussia, Pennsylvania, USA., Bril V; Ellen and Martin Prosserman Centre for Neuromuscular Diseases, Division of Neurology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada., Merkies ISJ; Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands.; Curaçao Medical Center, Willemstad, Curaçao., Bassett P; Meridian HealthComms Ltd, Manchester, UK., Cleasby A; Meridian HealthComms Ltd, Manchester, UK., van Schaik IN; Department of Neurology, Amsterdam University Medical Centres, Amsterdam, The Netherlands.; The Netherlands and Spaarne Gasthuis, Haarlem, The Netherlands.
Jazyk: angličtina
Zdroj: Journal of the peripheral nervous system : JPNS [J Peripher Nerv Syst] 2020 Sep; Vol. 25 (3), pp. 230-237. Date of Electronic Publication: 2020 Aug 05.
DOI: 10.1111/jns.12402
Abstrakt: The Polyneuropathy And Treatment with Hizentra (PATH) study required subjects with chronic inflammatory demyelinating polyneuropathy (CIDP) to show dependency on immunoglobulin G (IgG) and then be restabilized on IgG before being randomized to placebo or one of two doses of subcutaneous immunoglobulin (SCIG). Nineteen of the 51 subjects (37%) randomized to placebo did not relapse over the next 24 weeks. This article explores the reasons for this effect. A post-hoc analysis of the PATH placebo group was undertaken. A literature search identified other placebo-controlled CIDP trials for review and comparison. In PATH, subjects randomized to placebo who did not relapse were significantly older, had more severe disease, and took longer to deteriorate in the IgG dependency period compared with those who relapsed. Published trials in CIDP, whose primary endpoint was stability or deterioration, had a mean non-deterioration (placebo effect) of 43%, while trials with a primary endpoint of improvement had a placebo response of only 11%. Placebo is an important variable in the design of CIDP trials. Trials designed to show clinical improvement will have a significantly lower effect of this phenomenon than those designed to show stability or deterioration.
(© 2020 CSL Behring. Journal of the Peripheral Nervous System published by Wiley Periodicals LLC on behalf of Peripheral Nerve Society.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje